Complete Remission of Post-transplantation Recurrence of Focal Segmental Glomerulosclerosis With the Use of Adrenocorticotrophic Hormone Gel: Case Report

Transplant Proc. 2015 Sep;47(7):2219-22. doi: 10.1016/j.transproceed.2015.07.013.

Abstract

Background: Post-transplantation recurrence of primary focal and segmental glomerulosclerosis (FSGS) is estimated to occur in 30%-50% of cases and doubles the risk of allograft failure. Treatment of recurrent FSGS is challenging because specific pathogenic targets are unknown and available therapeutic options have limited efficacy.

Case report: We report a case of recurrent FSGS with nephrotic-range proteinuria (urine protein creatinine ratio [UPCR], >50) and debilitating edema that was resistant to rituximab and plasmapheresis. The patient had a remarkable response to adrenocorticotropic hormone (ACTH) gel and achieved complete remission (UPCR, 0.5; serum albumin, 4.1 g/dL; serum creatinine, 1.0 mg/dL) which was maintained over 10 months on this treatment.

Conclusions: We conclude that ACTH gel is a potential therapeutic option for post-transplantation recurrence of FSGS and warrants further evaluation.

Publication types

  • Case Reports

MeSH terms

  • Adrenocorticotropic Hormone / administration & dosage*
  • Aged, 80 and over
  • Biopsy
  • Edema / drug therapy
  • Glomerulosclerosis, Focal Segmental / drug therapy*
  • Glomerulosclerosis, Focal Segmental / etiology
  • Glomerulosclerosis, Focal Segmental / surgery
  • Humans
  • Kidney Transplantation
  • Male
  • Nephrotic Syndrome
  • Plasmapheresis / methods*
  • Postoperative Complications
  • Postoperative Period
  • Proteinuria / drug therapy
  • Recurrence
  • Remission Induction
  • Renal Insufficiency / therapy
  • Rituximab / therapeutic use
  • Treatment Outcome

Substances

  • Rituximab
  • Adrenocorticotropic Hormone